These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10991672)

  • 1. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies.
    Grünblatt E; Mandel S; Youdim MB
    J Neurol; 2000 Apr; 247 Suppl 2():II95-102. PubMed ID: 10991672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
    Grünblatt E; Mandel S; Youdim MB
    Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.
    Mandel S; Grünblatt E; Youdim M
    J Neural Transm Suppl; 2000; (60):117-24. PubMed ID: 11205134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
    Youdim MB
    J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
    Zhao Y; Zhang Q; Xi J; Xiao B; Li Y; Ma C
    Int J Clin Exp Pathol; 2015; 8(3):2354-64. PubMed ID: 26045742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
    Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
    Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
    Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress indices in Parkinson's disease : biochemical determination.
    Youdim MB; Drigues N; Mandel S
    Methods Mol Med; 2001; 62():137-53. PubMed ID: 21318773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.
    Son HJ; Lee JA; Shin N; Choi JH; Seo JW; Chi DY; Lee CS; Kim EM; Choe H; Hwang O
    Br J Pharmacol; 2012 Apr; 165(7):2213-27. PubMed ID: 21951056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
    Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
    Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
    Youdim MB; Grünblatt E; Mandel S
    Ann N Y Acad Sci; 1999; 890():7-25. PubMed ID: 10668410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.
    Laloux C; Petrault M; Lecointe C; Devos D; Bordet R
    Pharmacol Res; 2012 May; 65(5):514-22. PubMed ID: 22391246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.